OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud Lawsuit

Author's Avatar
Dec 20, 2023

PR Newswire

BENSALEM, Pa., Dec. 20, 2023 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK).

Class Period: December 29, 2022 – August 29, 2023

Lead Plaintiff Deadline: January 2, 2024

Investors suffering losses on their Outlook investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected].

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) there was a lack of substantial evidence supporting ONS-5010 as a

treatment for wet AMD; (2) Outlook and/or its manufacturing partner had deficient chemistry manufacturing and controls and other manufacturing issues for ONS-5010, which remained unresolved at the time the ONS-5010 BLA was resubmitted to the FDA; (3) as a result of all the foregoing, the FDA was unlikely to approve the ONS-5010 BLA in its present form; (4) accordingly, ONS-5010's regulatory and commercial prospects were overstated; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected], or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
[email protected]
www.howardsmithlaw.com

favicon.png?sn=PH98166&sd=2023-12-20 View original content:https://www.prnewswire.com/news-releases/otlk-investors-have-opportunity-to-lead-outlook-therapeutics-inc-securities-fraud-lawsuit-302019657.html

SOURCE Law Offices of Howard G. Smith

rt.gif?NewsItemId=PH98166&Transmission_Id=202312201100PR_NEWS_USPR_____PH98166&DateId=20231220